Lexicon Pharmaceuticals LXRX Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationTaxCreditsResearch.
The official record: Lexicon Pharmaceuticals’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount?
- Lexicon Pharmaceuticals (LXRX) reported effective income tax rate reconciliation, tax credit, research, amount of $236K in Q4 2025.
- How has Lexicon Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount changed year-over-year?
- Lexicon Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount decreased by 77.7% year-over-year, from $1.06M to $236K.
- What does effective income tax rate reconciliation, tax credit, research, amount mean?
- The total dollar amount of tax credits claimed by the company specifically related to qualified research and development expenditures. For biopharmaceutical companies, this represents a critical mechanism for offsetting the high costs of drug discovery and clinical trials.